-
Mashup Score: 0Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis - 13 hour(s) ago
These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Shawn Kwatra, MD, Reviews Late-Breaking Data of Abrocitinib for Prurigo Nodularis and Chronic Pruritus of Unknown Origin - 1 year(s) ago
Kwatra presented the abrocitinib data at EADV 2023.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
New: @drshawnkwatra , discusses new late-breaking data on the safety and efficacy of #abrocitinib for the treatment #PrurigoNodularis and chronic #pruritus of unknown origin presented at EADV 2023. https://t.co/9MEEdTpzWf
-
-
Mashup Score: 2Abrocitinib Did Not Impact Immune Responses to Vaccination in Adolescents With Atopic Dermatitis - 2 year(s) ago
A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
#Abrocitinib did not appear to have any effect or appreciable differences in immune responses to the tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine in an adolescent patient population with #AtopicDermatitis. #DermPAsummer https://t.co/hblQ5ZcMWz
-
-
Mashup Score: 0
Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Oral JAK-1 inhibitor #abrocitinib provided long-term efficacy in moderate to severe atopic dermatitis treatment among adult patients—regardless of older age status. New data from #RAD2023: https://t.co/OSq7dQKXgZ
-
-
Mashup Score: 0
Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
#Abrocitinib demonstrated an acceptable long-term safety profile in adolescents with #AtopicDermatitis across 1000 patient years, according to late-breaking research presented at #RAD2023. https://t.co/jOkZ1huFnP
-
-
Mashup Score: 1Abrocitinib Approved for Adolescents With Atopic Dermatitis - 2 year(s) ago
The expanded approval is based on data from a recent phase 3 clinical trial.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
The #FDA has approved a supplemental new drug application to expand the use of #abrocitinib from Pfizer for adolescents with moderate to severe #atopicdermatitis. https://t.co/N7EZ0mVn5G
-
-
Mashup Score: 0Karan Lal, DO: JAK Inhibitors, FDA Approval of Abrocitinib for Adolescents with Atopic Dermatitis - 2 year(s) ago
In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Karan Lal, DO, spoke about the effects of JAK inhibitors during a new interview with @MDMagazine. He also discussed the @US_FDA approval of #abrocitinib for adolescent #AtopicDermatitis patients: https://t.co/tUcezfiZCG https://t.co/AIPrBYVyIw
-
-
Mashup Score: 0Karan Lal, DO: JAK Inhibitors, FDA Approval of Abrocitinib for Adolescents with Atopic Dermatitis - 2 year(s) ago
In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
In an @MDMagazine interview, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and about the @US_FDA approval of #abrocitinib for younger #AtopicDermatitis patients. Check it out here: https://t.co/4hTWIoR1Au
-
-
Mashup Score: 0FDA approves Cibinqo for moderate to severe atopic dermatitis - 3 year(s) ago
The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.Supported by safety and efficacy data across three randomized, placebo-controlled phase 3 trials, cibinqo (abrocitinib, Pfizer) demonstrated a consistent safety profile and improved skin clearance, extent of disease severity and itch
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
. @US_FDA approves #cibinqo (#abrocitinib, @pfizer) for moderate to severe atopic #dermatitis @HealioDerm https://t.co/5bRfFXV6r6
-
-
Mashup Score: 0Abrocitinib approved for atopic dermatitis in Europe - 3 year(s) ago
Approval was based on the results of studies that include four phase 3 clinical trials and an ongoing open-label extension study.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
The oral JAK1 inhibitor #abrocitinib has been approved in Europe for the treatment of moderate to severe AD in adults. https://t.co/jkD4kxt2tg https://t.co/4SZ7O781ms
-
#Abrocitinib treatment of atopic dermatitis led to rapid improvements in disease severity, new findings suggest, and this was maintained up to the 72-week mark in patients for whom approved systemic drugs were inadequate. View our summary here: https://t.co/OY0XAAAwCf